 SAN DIEGO, Aug. 25, 2021 PRNewswire -- Cardiff Oncology, Inc. Nasdaq: CRDF, a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need including KRAS-mutated colorectal cancer, pancreatic cancer, and castrate-resistant prostate cancer, today announced that it will host a virtual KOL event for analysts, investors, and the scientific community on Wednesday, September 8, 2021. The webinar will include presentation of new data from Cardiff Oncologys Phase 1b2 clinical trial evaluating onvansertib in combination with standard-of-care FOLFIRIbevacizumab in KRAS-mutated mCRC, featuring the clinical trial principal investigator, Heinz-Josef Lenz, M.D. 